Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > irinotecan (Camptosar, CPT-11)

Irinotecan (Camptosar, CPT-11) : Pharmacia : Topoisomerase I inhibitor

Clinical Research in NSCLC
Clinical Research in SCLC
Side Effects

Clinical Research in NSCLC

Irinotecan & NSCLC - Recent MEDLINE Abstracts

Irinotecan & NSCLC - Clinical Trials (


Clinical Research in SCLC

Irinotecan Highly Active in Lung Cancer (
v.9, no. 11 (Suppl. 6) Oncology News (November 2000)
Summarizes research presented at the "Current Status of Irinotecan in Lung Cancer" seminar held at the 9th World Conference on Lung Cancer. Registration required for free access to [11/00]

Camptosar (irinotecan) Plus Cisplatin Increases Survival in Small Cell Lung Cancer (Doctor's Guide)
Reports that Camptosar (also known as irinotecan or CPT-11) in combination with cisplatin increased survival compared with the standard treatment (etoposide and cisplatin) for patients with extensive small cell lung cancer, according to a Phase III study presented at ASCO 2000. [5/00]

Irinotecan & SCLC - Recent MEDLINE Abstracts

Irinotecan & SCLC - Clinical Trials (


Side Effects

Camptosar (irinotecan) Treatment Guide (Medicine Online/Glaxo Wellcome)
Information on what to expect during treatment, possible side effects, controlling diarrhea, and when to call the doctor. See also the Camptosar Question & Answer Guide. (n.b., Camptosar information given here refers specifically to its use in the treatment of colon cancer.)


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 26-Apr-2011
Karen Parles, MLS Editor